(Q48500564)

12 February 2018

title

Motexafin gadolinium: a novel radiosensitizer for brain tumors. (English)

1 reference

12 February 2018

Minesh P Mehta

4

0 references

author name string

Dave Francis

1

1 reference

12 February 2018

Gregory M Richards

2

1 reference

12 February 2018

Afshin Forouzannia

3

1 reference

12 February 2018

Deepak Khuntia

5

1 reference

12 February 2018

language of work or name

English

0 references

publication date

1 September 2009

1 reference

12 February 2018

Expert Opinion on Pharmacotherapy

published in

1 reference

12 February 2018

volume

10

1 reference

12 February 2018

issue

13

1 reference

12 February 2018

page(s)

2171-2180

1 reference

12 February 2018

Whole-brain radiotherapy in the management of brain metastasis

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Single brain metastases: surgery plus radiation or radiation alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium: a novel radiosensitizer for brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Hypoxic radiosensitization: adored and ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Recent advances in the use of radiosensitizing nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Radiation techniques in neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Therapeutic management of metastatic brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium: a possible new radiosensitiser

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

A randomized trial of surgery in the treatment of single metastases to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903179325

10.1517/14656560903179325

21 January 2018

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018